{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:20:58Z","timestamp":1793038858761,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T00:00:00Z","timestamp":1484092800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s00125-016-4194-y","type":"journal-article","created":{"date-parts":[[2017,1,10]],"date-time":"2017-01-10T23:25:43Z","timestamp":1484090743000},"page":"395-398","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects"],"prefix":"10.1007","volume":"60","author":[{"given":"Roberto","family":"Vettor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio E.","family":"Inzucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Fioretto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,11]]},"reference":[{"key":"4194_CR1","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128","journal-title":"N Engl J Med"},{"key":"4194_CR2","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJ Heerspink","year":"2016","unstructured":"Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ (2016) Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134:752\u2013772","journal-title":"Circulation"},{"key":"4194_CR3","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2337\/dc16-0041","volume":"39","author":"M Abdul-Ghani","year":"2016","unstructured":"Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA (2016) SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME Study. Diabetes Care 39:717\u2013725","journal-title":"Diabetes Care"},{"key":"4194_CR4","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/dc16-0542","volume":"39","author":"S Mudaliar","year":"2016","unstructured":"Mudaliar S, Alloju S, Henry RR (2016) Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care 39:1115\u20131122","journal-title":"Diabetes Care"},{"key":"4194_CR5","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","volume":"39","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Mark M, Mayoux E (2016) CV protection in the EMPA-REG OUTCOME trial: a \u2018trifty substrate\u2019 hypothesis. Diabetes Care 39:1108\u20131114","journal-title":"Diabetes Care"},{"key":"4194_CR6","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","volume":"37","author":"D Fitchett","year":"2016","unstructured":"Fitchett D, Zinman B, Wanner C et al (2016) Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J 37:1526\u20131534","journal-title":"Eur Heart J"},{"key":"4194_CR7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"346","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H et al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 346:11\u201321","journal-title":"N Engl J Med"},{"key":"4194_CR8","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"E Ferrannini","year":"2014","unstructured":"Ferrannini E, Muscelli E, Frascerra S et al (2014) Metabolic response to sodium-glucose cotrans- porter 2 inhibition in type 2 diabetic patients. J Clin Invest 124:499\u2013508","journal-title":"J Clin Invest"},{"key":"4194_CR9","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","volume":"124","author":"A Merovci","year":"2014","unstructured":"Merovci A, Solis-Herrera C, Daniele G et al (2014) Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 124:509\u2013514","journal-title":"J Clin Invest"},{"key":"4194_CR10","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1136\/hrt.32.3.307","volume":"32","author":"JG Murtagh","year":"1970","unstructured":"Murtagh JG, Binnion PF, Lal S, Hutchison KJ, Fletcher E (1970) Haemodynamic effects of glucagon. Br Heart J 32:307\u2013315","journal-title":"Br Heart J"},{"key":"4194_CR11","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1161\/01.CIR.45.3.534","volume":"45","author":"R Lvoff","year":"1972","unstructured":"Lvoff R, Wilcken DE (1972) Glucagon in heart failure and in cardiogenic shock. Experience in 50 patients. Circulation 45:534\u2013542","journal-title":"Circulation"},{"key":"4194_CR12","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1161\/CIRCRESAHA.113.300376","volume":"113","author":"T Doenst","year":"2013","unstructured":"Doenst T, Nguyen TD, Abel ED (2013) Cardiac metabolism in heart failure: implications beyond ATP production. Circ Res 113:709\u2013724","journal-title":"Circ Res"},{"key":"4194_CR13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.yjmcc.2012.09.002","volume":"55","author":"MG Rosca","year":"2013","unstructured":"Rosca MG, Tandler B, Hoppel CL (2013) Mitochondria in cardiac hypertrophy and heart failure. J Mol Cell Cardiol 55:31\u201341","journal-title":"J Mol Cell Cardiol"},{"key":"4194_CR14","doi-asserted-by":"crossref","first-page":"E519","DOI":"10.1152\/ajpendo.00617.2013","volume":"306","author":"R Vettor","year":"2014","unstructured":"Vettor R, Valerio A, Ragni M et al (2014) Exercise training boosts eNOS-dependent mitochondrial biogenesis in mouse heart: role in adaptation of glucose metabolism. Am J Physiol Endocrinol Metab 306:E519\u2013E528","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"4194_CR15","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1161\/01.RES.0000259591.97107.6c","volume":"100","author":"E Nisoli","year":"2007","unstructured":"Nisoli E, Clementi E, Carruba MO, Moncada S (2007) Defective mitochondrial biogenesis: a hallmark of the high cardiovascular risk in the metabolic syndrome? Circ Res 100:795\u2013806","journal-title":"Circ Res"},{"key":"4194_CR16","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.cger.2009.07.002","volume":"25","author":"E Marzetti","year":"2009","unstructured":"Marzetti E, Wohlgemuth SE, Anton SD, Bernabei R, Carter CS, Leeuwenburgh C (2009) Cellular mechanisms of cardioprotection by calorie restriction: state of the science and future perspectives. Clin Geriatr Med 25:715\u2013732","journal-title":"Clin Geriatr Med"},{"key":"4194_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-4134-x","author":"A Baartscheer","year":"2016","unstructured":"Baartscheer A, Schumacher CA, W\u00fcst RCI et al (2016) Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+\/H+ exchanger in rats and rabbits. Diabetologia. doi: 10.1007\/s00125-016-4134-x","journal-title":"Diabetologia"},{"key":"4194_CR18","doi-asserted-by":"crossref","first-page":"e002183","DOI":"10.1161\/JAHA.115.002183","volume":"4","author":"R Lambert","year":"2015","unstructured":"Lambert R, Srodulski S, Peng X, Margulies KB, Despa F, Despa S (2015) Intracellular Na+ concentration ([Na+]i) is elevated in diabetic hearts due to enhanced Na+-glucose cotransport. J Am Heart Assoc 4:e002183","journal-title":"J Am Heart Assoc"},{"key":"4194_CR19","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1161\/01.RES.0000232546.92777.05","volume":"99","author":"C Maack","year":"2006","unstructured":"Maack C, Cortassa S, Aon MA, Ganesan AN, Liu T, O\u2019Rourke B (2006) Elevated cytosolic Na+ decreases mitochondrial Ca2+ uptake during excitation\u2013contraction coupling and impairs energetic adaptation in cardiac myocytes. Circ Res 99:172\u2013182","journal-title":"Circ Res"},{"key":"4194_CR20","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1161\/CIRCULATIONAHA.106.626929","volume":"115","author":"HE Cingolani","year":"2007","unstructured":"Cingolani HE, Ennis IL (2007) Sodium-hydrogen exchanger, cardiac overload, and myocardial hypertrophy. Circulation 115:1090\u20131100","journal-title":"Circulation"},{"key":"4194_CR21","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.bbabio.2010.02.022","volume":"1797","author":"EJ Griffiths","year":"2010","unstructured":"Griffiths EJ, Balaska D, Cheng WH (2010) The ups and downs of mitochondrial calcium signalling in the heart. Biochim Biophys Acta 1797:856\u2013864","journal-title":"Biochim Biophys Acta"},{"key":"4194_CR22","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrm3412","volume":"13","author":"R Rizzuto","year":"2012","unstructured":"Rizzuto R, De Stefani D, Raffaello A, Mammucari C (2012) Mitochondria as sensors and regulators of calcium signalling. Nat Rev Mol Cell Biol 13:566\u2013578","journal-title":"Nat Rev Mol Cell Biol"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-016-4194-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-016-4194-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-016-4194-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T07:52:12Z","timestamp":1498377132000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-016-4194-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,11]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["4194"],"URL":"https:\/\/doi.org\/10.1007\/s00125-016-4194-y","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,11]]}}}